Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation
From General Health to Pharmaceutical Safety
For decades, general health and science information has served as the foundation for public understanding of medical risks, emphasizing broad lifestyle factors and environmental exposures. Within this legacy framework, discussions of cancer risk have traditionally focused on well-established contributors such as smoking, UV radiation, and viral infections. This background provides essential context for evaluating emerging pharmaceutical safety questions, particularly those involving immunomodulatory agents used in oncology. Transitioning from this general health perspective, occupational exposure concerns now warrant focused attention. The therapeutic use of Avelumab, a PD-L1 inhibitor approved for Merkel cell carcinoma, has prompted investigations into whether the drug itself may influence cancer risk in treated populations. While the legacy context emphasizes preventive behaviors and known carcinogens, the current inquiry shifts toward understanding potential causation pathways in patients receiving this immunotherapy. Studies examining Avelumab exposure and subsequent Merkel cell carcinoma risk represent a departure from traditional environmental risk assessment, moving into the realm of drug-induced oncogenesis. This pivot requires careful consideration of exposure contexts—therapeutic versus occupational—and the distinct mechanisms by which immune checkpoint modulation might alter tumor surveillance. The transition from general health literacy to specialized pharmacovigilance underscores the need for rigorous epidemiological evaluation of Avelumab's risk profile in both clinical and occupational settings.
Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).
Evidence on Causation: Avelumab as Treatment, Not Cause
The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but rather of therapeutic intervention. Avelumab is used to treat MCC, not to cause it. The evidence indicates that avelumab functions as an immune checkpoint inhibitor that blocks PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. In the context of MCC, avelumab has demonstrated efficacy in inducing objective responses in a subset of patients. For patients who are refractory to avelumab, alternative treatment options are being explored. For example, a retrospective study of patients with metastatic MCC refractory to the PD-L1 inhibitor avelumab who were later treated with combined ipilimumab and nivolumab found that three out of five patients responded according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that ipilimumab plus nivolumab was used in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study examined ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding risk anchors, the adequacy of warnings about avelumab and MCC must be considered in light of the drug's approved indication. Avelumab is indicated for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events, which are common to immune checkpoint inhibitors. The evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. Causation-related considerations for affected patients should focus on the natural history of MCC and the role of avelumab as a therapeutic agent. The timeline between exposure to avelumab and documented harm is relevant to adverse events, not to the development of MCC. Immune-related adverse events can occur during treatment with avelumab, and their timing varies. However, the evidence does not provide a specific timeline for harm related to MCC causation, as avelumab is not a causative agent.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor that blocks PD-L1 to help the immune system attack cancer cells. Studies show it is effective in treating metastatic MCC, and there is no evidence that it causes the disease.
What is the evidence for avelumab's role in Merkel cell carcinoma?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.